Adventist Health Bakersfield is first in Kern County to use Noah Medical's next-generation, robotic-assisted bronchoscopy for earlier lung cancer diagnosis
G
Read full storyGlobe Newswire
Original source
Trending
Where the enterprise AI advantage comes fromCapitol agenda: Senate GOP eyes exit plan as trail callsWoman sues Oregon hospital for $17.5M. Lawsuit says doctor misdiagnosed parasite that nearly killed herCedar Mill Cider Festival on tap this weekendWalla Walla Valley weekend picks: Become a 'bark' ranger, celebrate Harry PotterHere are the conservative priorities stalled as the lameHouthis accuse Saudis of deadly strikes as thousands flee escalating conflictSonia Gandhi Voter Roll Row: Delhi Court Revives Probe Into 1980 Electoral Roll EntryWhere the enterprise AI advantage comes fromCapitol agenda: Senate GOP eyes exit plan as trail callsWoman sues Oregon hospital for $17.5M. Lawsuit says doctor misdiagnosed parasite that nearly killed herCedar Mill Cider Festival on tap this weekendWalla Walla Valley weekend picks: Become a 'bark' ranger, celebrate Harry PotterHere are the conservative priorities stalled as the lameHouthis accuse Saudis of deadly strikes as thousands flee escalating conflictSonia Gandhi Voter Roll Row: Delhi Court Revives Probe Into 1980 Electoral Roll Entry
Related Stories
Health2h ago
Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Envisagenics today announced a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate selected tumor-specific targets for the development of first-in-class precision therapies for people living with solid tumors. Envisagenics has pioneered an artificial intelligence (AI)-powered approach that is transforming alternative RNA splicing into a new frontier for drug discovery.
GGlobe Newswire
Health2h ago
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.
GGlobe Newswire
Health2h ago
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- -- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO)
GGlobe Newswire
Health2h ago
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.
FFinancialcontent